NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation

What happened: NFL Biosciences received ANSM and CPP approvals to begin its Phase 2 TONIC trial of NFL-102 for smoking and nicotine cessation. Key numbers: 310 smokers planned; Part A covers the first 40 participants, Part B the next 270. Part A enrollment scheduled for November 2026, Part A results expected April 2027. Why it matters: The company states its current cash position funds only Part A, and it is seeking strategic and financial partners for Part B. Part A and Part B milestones will be the subject of dedicated announcements.

NFL Biosciences received ANSM and CPP approvals to begin its Phase 2 TONIC trial of NFL-102 for smoking and nicotine cessation.

The company states its current cash position funds only Part A, and it is seeking strategic and financial partners for Part B. Part A and Part B milestones will be the subject of dedicated announcements.